

Subject: 1. NCI DRUG DELIVERY 2. DRUG TRANSPORT		Issued By: IDS PHARMACY	
		Approved By: Kathleen R. Hurtado R.Ph. President & CEO	
Policy #: 2031	Issue Date: May 30, 2008	Revised Date: August 4, 2009	Effective Date: August 4, 2009

PURPOSE

1. To ensure proper communication between Norris Pharmacy and IDS Pharmacy prior to the delivery of study products for LA County research participants accruing into NCI (National Cancer Institute) studies in order to comply with the California Board of Pharmacy’s requirements for pre-dispensation labeling.
2. To ensure proper communication between Norris Pharmacy and IDS Pharmacy prior to the delivery of study products for Norris research participants in order to comply with the California Board of Pharmacy’s requirements for pre-dispensation labeling.

POLICY

1. **LABELING:**

- a. All medications stored at Norris pharmacy for LA County Research Participants who are accrued into NCI studies must be delivered to the IDS Pharmacy for appropriate labeling before dispensing to the research participant via study nurse/coordinator.
- b. All medications stored at IDS Pharmacy for Norris research participants must be delivered to Norris Pharmacy for appropriate labeling before dispensing to the research participant via study nurse/coordinator.
- c. All study products must be received and checked by pharmacy department staff before being sent to infusion center.

2. **STUDY ACCRUAL NOTIFICATION:**

- a. Study teams must inform IDS Pharmacy staff that LA County research participants will be accruing into a study at least 1 to 2 days before study products are to be delivered to the IDS Pharmacy.
- b. Study teams must inform IDS Pharmacy staff that Norris research participants will be accruing into a study at least 1 to 2 days before study products are to be delivered to Norris Pharmacy.

3. **STUDY PRODUCT TRANSPORT:** Study products will be transported via approved personnel in an insulated container.

Subject: 1. NCI DRUG DELIVERY 2. DRUG TRANSPORT		Issued By: IDS PHARMACY	
		Approved By: Kathleen R. Hurtado R.Ph. President & CEO	
Policy #: 2031	Issue Date: May 30, 2008	Revised Date: August 4, 2009	Effective Date: August 4, 2009

RESPONSIBILITY

Principal Investigators
Norris Pharmacist-in-Charge
IDS Pharmacist-in-Charge
IDS Staff
Norris Staff